Endovascular Treatment for Mild Stroke Caused by a Blocked Basilar Artery
Compares a clot-removal procedure with medical care in adults with mild basilar artery occlusion.
Plain-language title generated from the registry record
Registry title: The Efficacy and Safety of Endovascular Treatment for Acute Mild Basilar Artery Occlusion
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a recent, mild stroke caused by a blocked basilar artery in the back of the brain. It tests a procedure to reopen the artery.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Stroke in the back part of the brain, within 24 hours of onset, with a blocked basilar artery seen on CTA, MRA or DSA. NIHSS score of 2 or more and under 10. Brain scan shows pc-ASPECTS of 6 or more, or Pons-Midbrain Index under 3.
Main reasons for not taking part
- Bleeding in the brain on imaging before randomization
- Pregnant or breast-feeding
- Known bleeding tendency, or blood-thinner tablets with INR above 1.5
- Life expectancy under 1 year
- Taking part in another drug or device trial now or within the next 3 months
Read by machine on 9 November 2026.
Where in China
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaContact: Feng Gao, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Feng Gao
- Trial code
- NCT07390032
- Record updated
- 5 February 2026
- Original description
This study assesses the efficacy and safety of endovascular treatment for acute mild basilar artery occlusion within a multicenter, prospective, open-label, endpoint-blinded, randomized controlled clinical trial.Read full original descriptionShow less
The Efficacy and Safety of Endovascular Treatment for Acute Mild Basilar Artery Occlusion: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial
This study assesses the efficacy and safety of endovascular treatment for acute mild basilar artery occlusion within a multicenter, prospective, open-label, endpoint-blinded, randomized controlled clinical trial.
Inclusion: Age≥18; Acute ischemic stroke in posterior circulation, the time from stroke onset (or finally found normal) to randomization was within 24 hours; Acute basilar artery occlusion confirmed by CTA,MRA,or DSA; NIHSS score≥2 points and<10 points from the onset of the disease to before randomization; Posterior circulation large core infarction:NCCT or DWI showed pc-ASPECTS≥6, or Pons-Midbrain Index (PMI)<3; No significant functional disability before stroke (mRS≤2 points); Each patient or their legal representative must provide written informed consent before enrolment.
Exclusion: Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization; Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months; Acute cerebral infarction occurred within 48 hours after cardio cerebral vascular intervention or major surgery (patients over 48 hours can be included in the group); History of contraindication for contrast medium (except mild rash); Refractory hypertension (defined as systolic blood pressure>185 mmHg or diastolic blood pressure>110 mmHg) that cannot be controlled by drug treatment; Patients whose life expectancy is less than 1 year (such as patients with malignant tumor, advanced cardiopulmonary disease, etc.); Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up; It is known that patients with dementia or mental illness cannot complete neurological function assessment and follow-up; Any other condition (in the opinion of the site investigator) that inappropriate to participate this study; Known hereditary or acquired bleeding tendency, lack of coagulation factors, or oral anticoagulants with INR>1.5; Blood glucose<2.8 or>22.2 mmol/L; Platelet count<100*109/L, serum creatinine>2.0 g/L (177 μ mol/L), or glomerular filtration rate<30 ml/(min*1.73 m2); Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging; Known or highly suspected chronic occlusion of basilar artery; CTA/MRA/DSA confirmed occlusion of anterior and posterior circulation; Severe stenosis, arterial dissection, or excessive tortuosity of the extracranial or intracranial segments of the vertebral artery may result in the inability of interventional instruments to be successfully delivered or positioned; Current pregnant or breast-feeding; Central nervous system vasculitis has been diagnosed or clinically suspected.